Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to confirm the efficacy of 60 mg of MCI-186 via
intravenous drip once a day in patients with ALS based on the changes in the revised ALS
functional rating scale (ALSFRS-R) scores after 24 weeks administration in double-blind,
placebo-controlled manner. And in addition, this study will be performed to examine the
safety of MCI-186 to ALS patients.